Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aldeyra Therapeutics, Inc.

< Previous 1 2 3 Next >
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Host Investor Roundtable Q&A
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.